Logo

IPSC

Century Therapeutics, Inc.

IPSC

Century Therapeutics, Inc. • NASDAQ
$0.55 ▲ 0.98% (+0.01)
Market Cap $46.93 M
52w High $1.83
52w Low $0.34
Dividend Yield 0%
P/E -1.7
Volume 253.38K
Outstanding Shares 86.06M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $25.993M ▼ $-34.422M ▼ 0% $-0.4 ▼ $-31.293M ▼
Q2-2025 $0 ▼ $31.08M ▼ $-32.541M ▼ 0% ▼ $-0.38 ▼ $-29.34M ▼
Q1-2025 $109.164M ▲ $34.988M ▼ $76.56M ▲ 70.133% ▲ $0.89 ▲ $77.397M ▲
Q4-2024 $4.173M ▲ $41.457M ▲ $-36.073M ▼ -864.438% ▲ $-0.46 ▼ $-30.979M ▼
Q3-2024 $791K $35.58M $-31.226M -3.948K% $-0.37 $-27.936M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $132.749M ▼ $244.717M ▼ $68.369M ▼ $176.348M ▼
Q2-2025 $155.843M ▼ $284.692M ▼ $74.794M ▼ $209.898M ▼
Q1-2025 $165.121M ▼ $315.609M ▼ $75.17M ▼ $240.439M ▲
Q4-2024 $189.292M ▼ $353.216M ▼ $191.854M ▼ $161.362M ▼
Q3-2024 $198.112M $388.617M $192.931M $195.686M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-34.428M ▼ $-25.584M ▲ $24.671M ▼ $0 $-913K ▼ $-25.779M ▲
Q2-2025 $-32.541M ▼ $-27.592M ▲ $32.539M ▲ $0 ▼ $4.947M ▲ $-27.909M ▲
Q1-2025 $76.56M ▲ $-34.623M ▼ $27.93M ▼ $120K ▲ $-6.573M ▼ $-34.623M ▼
Q4-2024 $-36.073M ▼ $-24.223M ▲ $30.606M ▼ $-602K ▼ $5.781M ▼ $-24.377M ▲
Q3-2024 $-31.226M $-28.332M $39.199M $273K $11.136M $-27.528M

Five-Year Company Overview

Income Statement

Income Statement Century Therapeutics is still very much in the “development” rather than “commercial” phase. Revenue is essentially negligible, so the company is not yet generating meaningful sales from its technology or partnerships. Most of its spending goes into research and development and general operations, which leads to steady, sizable losses each year. These losses have been fairly consistent over time, reflecting ongoing investment rather than sudden cost spikes or dramatic cutbacks. Earnings per share remain deeply negative, which is typical for an early-stage biotech that has not yet brought a product to market.

Balance Sheet

Balance Sheet The balance sheet shows a company that still has a meaningful base of assets and cash, but one that has been drawing down its financial cushion over time. Cash makes up an important, though not dominant, portion of total assets, indicating some funding runway but not an unlimited one. Debt is present but remains modest relative to the overall size of the company, so leverage does not appear to be a central risk right now. Shareholders’ equity has declined from earlier years as losses accumulate, but it remains positive, suggesting that, so far, the company has been funding itself primarily through equity capital rather than heavy borrowing.

Cash Flow

Cash Flow Cash flows underline the profile of a classic clinical-stage biotech: the business consumes cash rather than generates it. Operating cash flow is consistently negative, driven largely by research and development spending and the absence of product revenue. Free cash flow is also negative, showing that the company needs external financing to sustain its activities. Capital expenditures are relatively low, which means most of the cash burn is tied to running trials, paying staff, and advancing the pipeline, not building large facilities. There are small year-to-year fluctuations, but the overall pattern is a steady cash outflow that must be supported by cash on hand and future funding.

Competitive Edge

Competitive Edge Century operates in a highly competitive and fast-moving area of biotechnology: off-the-shelf cell therapies. Its main edge lies in its induced pluripotent stem cell platform and its Allo-Evasion technology, both designed to create scalable, repeat-dose cell therapies that can avoid immune rejection. A major pharmaceutical partnership adds external validation, resources, and potential commercial pathways, which strengthens its position versus smaller peers. The company also benefits from an expanding patent portfolio and a diversified pipeline that spans blood cancers, autoimmune diseases, and diabetes. At the same time, it competes against other well-funded players pursuing similar allogeneic approaches, and it remains much smaller and less resourced than large pharma companies. Clinical success, regulatory progress, and manufacturing execution will heavily influence whether its current technological advantages translate into lasting competitive strength.

Innovation and R&D

Innovation and R&D Innovation is the core of Century’s identity and spending. The company is built around an iPSC-based platform that allows precise genetic editing and large-scale, standardized manufacturing of therapeutic cells. Its Allo-Evasion toolkit aims to make truly off-the-shelf products possible, with repeat dosing and reduced need for harsh immune suppression. The pipeline is relatively broad for a company at this stage, led by a flagship oncology candidate and expanding into autoimmune disease and Type 1 diabetes, which opens several potential paths to value creation. Early clinical data in blood cancers looks encouraging on safety and early activity, but remains preliminary. Overall, R&D intensity is high, scientific ambition is notable, and the main question is not whether the company is innovating, but how reliably those innovations will turn into safe, effective, and approvable therapies.

Summary

Century Therapeutics is a classic high-science, high-risk, early-stage biotech. Financially, it has almost no revenue, runs consistent losses, and uses up cash each year to fund research and clinical work, relying on its cash reserves and capital markets to operate. Its balance sheet shows some remaining strength and only modest debt, but also a clear trend of erosion as losses accumulate. Strategically, the company is differentiated by its iPSC platform and immune-evasion technology, supported by a notable pharma partnership and a growing intellectual property estate. The pipeline is diverse and ambitious, reaching beyond oncology into autoimmune conditions and diabetes. The key uncertainties revolve around clinical trial outcomes, regulatory paths, future financing, and how well it can stand out in a crowded allogeneic cell therapy field. In short, the story is driven far more by scientific and clinical milestones than by current financial performance.

NEWS

November 25, 2025 · 4:01 PM UTC

Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference

Read more

November 13, 2025 · 7:30 AM UTC

Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Read more

November 13, 2025 · 7:00 AM UTC

Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes

Read more

October 14, 2025 · 4:01 PM UTC

Century Therapeutics to Present at Chardan's 9th Annual Genetic Medicines Conference

Read more